Market Overview

UPDATE: Stifel Nicolaus Raises PT to $9 on Boston Scientific Corporation Post Analyst Day

Share:
Related BSX
Earnings Scheduled For July 23, 2015
Boston Scientific Initiates Study Evaluating New Fully Resorbable Scaffold Technology
Should You Buy Evolving Trends in Medical Devices? - Industry Outlook (Zacks)

Stifel Nicolaus maintained Boston Scientific Corporation (NYSE: BSX) with a Buy rating and raised the price target from $8.00 to $9.00.

Stifel Nicolaus noted, "We left yesterday's Boston Scientific New York Analyst Day believing our basic thesis on BSX shares is unchanged. If anything, we left with increased conviction that after three years of negative top-line growth, BSX now has in place multiple avenues to re-accelerate sales growth back to mid-single digits by the 2016-2017 time frame. … Also evident throughout the meeting was the strong management team now in place at BSX and their clear and energetic strategic vision for the company. Overall, management laid out what we thought was a well thought-out and realistic plan to improve the growth and profitability prospects of the company."

Boston Scientific Corporation closed at $7.59 on Tuesday.

Latest Ratings for BSX

DateFirmActionFromTo
Jul 2015Stifel NicolausMaintainsBuy
Jul 2015Stephens & Co.Initiates Coverage onOverweight
Apr 2015BarclaysMaintainsOverweight

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Analyst Ratings

 

Related Articles (BSX)

Get Benzinga's Newsletters